Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035529 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00035529: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00035529 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035529, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Interventions
- DRUG Placebo
- DRUG BMS 188667 (Abatacept)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Why NCT00035529 stopped before completion
NCT00035529 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00035529 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035529 about?
NCT00035529 is a clinical study titled "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis". The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
What is the current status of trial NCT00035529?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-11. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00035529?
The interventions under investigation include: Placebo (DRUG), BMS 188667 (Abatacept) (DRUG).
Who is sponsoring clinical trial NCT00035529?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia